BR0114430A - Processos para a indução da morte de células cancerìgenas e para a regressão de tumor - Google Patents

Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Info

Publication number
BR0114430A
BR0114430A BR0114430-8A BR0114430A BR0114430A BR 0114430 A BR0114430 A BR 0114430A BR 0114430 A BR0114430 A BR 0114430A BR 0114430 A BR0114430 A BR 0114430A
Authority
BR
Brazil
Prior art keywords
cell death
cancer cell
processes
tumor regression
death induction
Prior art date
Application number
BR0114430-8A
Other languages
English (en)
Portuguese (pt)
Inventor
George Q Daley
Original Assignee
George Q Daley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Q Daley filed Critical George Q Daley
Publication of BR0114430A publication Critical patent/BR0114430A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0114430-8A 2000-10-05 2001-10-05 Processos para a indução da morte de células cancerìgenas e para a regressão de tumor BR0114430A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (1)

Publication Number Publication Date
BR0114430A true BR0114430A (pt) 2004-01-06

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114430-8A BR0114430A (pt) 2000-10-05 2001-10-05 Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Country Status (14)

Country Link
US (1) US6777415B2 (enExample)
EP (1) EP1322334A2 (enExample)
JP (1) JP2004510733A (enExample)
CN (1) CN1479630A (enExample)
AU (2) AU1186202A (enExample)
BR (1) BR0114430A (enExample)
CA (1) CA2424797C (enExample)
HK (1) HK1052870A1 (enExample)
HU (1) HUP0302913A3 (enExample)
MX (1) MXPA03003011A (enExample)
NO (1) NO20031531L (enExample)
NZ (1) NZ524936A (enExample)
WO (1) WO2002028381A2 (enExample)
ZA (1) ZA200302523B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
CA2477953A1 (en) * 2002-03-01 2003-09-12 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
AU2004289256A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
ATE521893T1 (de) * 2005-11-11 2011-09-15 Roger Williams Hospital P66-shc als prädiktiver marker bei der krebsbehandlung
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665341B2 (en) 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
CA2293706C (en) * 1997-06-17 2008-11-18 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
WO1998057945A1 (en) 1997-06-17 1998-12-23 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
CA2369895C (en) * 1999-01-11 2010-12-21 Princeton University High affinity inhibitors for target validation and uses thereof
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US7238525B2 (en) * 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
US20020128280A1 (en) 2002-09-12
HK1052870A1 (zh) 2003-10-03
MXPA03003011A (es) 2003-07-14
NO20031531L (no) 2003-06-05
CA2424797A1 (en) 2002-04-11
WO2002028381A3 (en) 2003-03-27
CN1479630A (zh) 2004-03-03
ZA200302523B (en) 2004-08-24
HUP0302913A2 (hu) 2003-12-29
JP2004510733A (ja) 2004-04-08
AU1186202A (en) 2002-04-15
NO20031531D0 (no) 2003-04-04
CA2424797C (en) 2009-12-29
US6777415B2 (en) 2004-08-17
NZ524936A (en) 2005-08-26
HUP0302913A3 (en) 2005-05-30
AU2002211862B2 (en) 2007-03-15
WO2002028381A2 (en) 2002-04-11
EP1322334A2 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
BR0114430A (pt) Processos para a indução da morte de células cancerìgenas e para a regressão de tumor
MX2023014405A (es) Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii.
BR9810465A (pt) Inibidores da farnesiltransferase de proteìnas
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
GB9807639D0 (en) Anti-inflammatory agents
AR027355A1 (es) Acidos tiazolidincarboxilicos
ATE281431T1 (de) Resorcin-derivate
NO20000752L (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
BR0211978A (pt) Terapia de combinação para o tratamento de câncer
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
AR025885A1 (es) Derivados del acido indolil-3-glioxilico con valiosas propiedades terapeuticas
PT1195159E (pt) Combinacao terapeutica de ascorbato com lisina e arginina para prevencao e tratamento do cancro
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
BR0213181A (pt) Combinações de inibidor de cox-2
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
PA8506201A1 (es) Quimioterapia de combinacion (combination chemotherapy)
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
ECSP003417A (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
TR200302193T4 (tr) Kombinasyon kemoterapisi.
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
BR0113582A (pt) Tienopirimidinas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.